Please use this identifier to cite or link to this item: https://open.uns.ac.rs/handle/123456789/3685
Title: Autoimmune thyroid diseases in patients with chronic hepatitis C treated by pegylated interferonalpha and ribavirin - A prospective study
Authors: Maja Ružić 
Milotka Fabri
Milica Medić Stojanoska 
Ivana Bajkin 
Vesna Turkulov 
Ludovico Abenavoli
Keywords: chronic hepatitis C;autoimmune thyroid diseases;pegylated interferon alfa;ribavirin
Issue Date: 1-Jan-2017
Journal: Srpski Arhiv za Celokupno Lekarstvo
Abstract: © 2017, Serbia Medical Society. All rights reserved. Introduction/Objective Despite sufficiently explained pathogenesis, today autoimmune thyroid diseases (AITD) are recognized as one of extra-hepatic manifestations of systemic hepatitis C virus infection. The aim of the present study was to determine clinical characteristics and to estimate the success of pegylated interferon-α2a plus ribavirin (pegIFN-α2a + RBV) therapy in patients with AITD as an extrahepatic manifestation of chronic hepatitis C infection (CHC). Methods This prospective study included 91 CHC patients treated with pegIFN-α2a + RBV from 2010 to 2012 (39 women and 52 men, mean age 41.6 ± 11.9). The study group (group A) consisted of 31 patients with CHC and AITD. Control group (group B) consisted of 60 patients with CHC without AITD. We analyzed clinical, biochemical, virological, and histopathological markers of CHC, as well as response and side effects of pegIFN-α2a + RBV therapy. Results There was a statistically significant difference in sex (p = 0.011), age (p = 0.001), AST level (p = 0.013), level of gamma globulins (p < 0.001), level of IgM (p = 0.007), IgG (p < 0.001), in the success of therapy of CHC with pegIFN-α2a + RBV between the groups. Odds ratio (OR) for unfavorable outcome in group A was 4.200 [95% confidence interval (CI): 1.545-11.417]. In final multivariate logistic regression analysis in group A, the only factor predicting sustained virological response was patients’ age (OR = 0.781; 95% CI: 0.603-0.959). The main side effects in group A were interferon induced thyroiditis (IIT) (41.9% vs. 3.3%; p < 0.001) and anemia, which was the only reason for dose reduction of ribavirin (29% vs. 6.7%; p = 0.027). Conclusion Patients with AITD as an extra-hepatic manifestation of CHC achieve poorer virological response and their antiviral therapy is inevitably followed by a manifestation of adverse effects, predominantly solvable IITs and anemia.
URI: https://open.uns.ac.rs/handle/123456789/3685
ISSN: 3708179
DOI: 10.2298/SARH160328007R
Appears in Collections:MDF Publikacije/Publications

Show full item record

Page view(s)

37
Last Week
10
Last month
6
checked on May 10, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.